Bevacizumab (Avastin®) is FDA approved for brain cancer (Han et al., 2014), but this monoclonal antibody (MAb) does not cross the non-disrupted BBB (Liu et al., 2016), and works by sequestration of vascular endothelial growth factor (VEGF) within the blood volume of the tumor. Here, VEGFA is linked to neoplasm.